JPH08231404A - 経鼻、経舌下、経直腸及び経皮投与のためのｎａｄｈ及びｎａｄｐｈ治療剤 - Google Patents

経鼻、経舌下、経直腸及び経皮投与のためのｎａｄｈ及びｎａｄｐｈ治療剤

Info

Publication number
JPH08231404A
JPH08231404A JP8005513A JP551396A JPH08231404A JP H08231404 A JPH08231404 A JP H08231404A JP 8005513 A JP8005513 A JP 8005513A JP 551396 A JP551396 A JP 551396A JP H08231404 A JPH08231404 A JP H08231404A
Authority
JP
Japan
Prior art keywords
nadh
nadph
disease
administered
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8005513A
Other languages
English (en)
Japanese (ja)
Inventor
Joerg G D Birkmayer
ジー．ディー．バークメーヤー ジョージ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Birkmayer USA
Original Assignee
Birkmayer USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Birkmayer USA filed Critical Birkmayer USA
Publication of JPH08231404A publication Critical patent/JPH08231404A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
    • A61K8/8176—Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP8005513A 1995-01-17 1996-01-17 経鼻、経舌下、経直腸及び経皮投与のためのｎａｄｈ及びｎａｄｐｈ治療剤 Pending JPH08231404A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37314795A 1995-01-17 1995-01-17
US373147 1995-01-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2003193159A Division JP2004002446A (ja) 1995-01-17 2003-07-07 経鼻、経舌下、経直腸及び経皮投与のためのｎａｄｈ及びｎａｄｐｈ治療剤

Publications (1)

Publication Number Publication Date
JPH08231404A true JPH08231404A (ja) 1996-09-10

Family

ID=23471176

Family Applications (2)

Application Number Title Priority Date Filing Date
JP8005513A Pending JPH08231404A (ja) 1995-01-17 1996-01-17 経鼻、経舌下、経直腸及び経皮投与のためのｎａｄｈ及びｎａｄｐｈ治療剤
JP2003193159A Pending JP2004002446A (ja) 1995-01-17 2003-07-07 経鼻、経舌下、経直腸及び経皮投与のためのｎａｄｈ及びｎａｄｐｈ治療剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2003193159A Pending JP2004002446A (ja) 1995-01-17 2003-07-07 経鼻、経舌下、経直腸及び経皮投与のためのｎａｄｈ及びｎａｄｐｈ治療剤

Country Status (4)

Country Link
US (3) US5654288A (enExample)
EP (1) EP0722734A1 (enExample)
JP (2) JPH08231404A (enExample)
CA (2) CA2167104A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531490A (ja) * 1998-12-09 2002-09-24 カイロン コーポレイション 中枢神経系に薬剤を投与するための方法
JP2006512320A (ja) * 2002-11-19 2006-04-13 ヌートロピア エアネールングスメディツィニッシェ フォーシューンクス ゲゼルシャフト ミット ベシュレンクテル ハフトング Ｎａｄｈ／ｎａｄｐｈを含む組成物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339073B1 (en) * 1997-09-11 2002-01-15 Oxigene, Inc. Uses of nicotinamide adenine dinucleotide and its derivatives for treatment of malignant and infectious diseases
US6340474B1 (en) 1999-08-03 2002-01-22 Charles A. Mesko Composition for potentiating a growth hormone and a method for preparation of said composition
DE10004547A1 (de) * 2000-02-02 2001-08-09 Liedtke Pharmed Gmbh Verfahren zur selektiven Verabreichung zentralnervös aktiver Stoffe
US20020177614A1 (en) * 2001-03-23 2002-11-28 Merril Carl R. Methods for treating nuerodegenerative diseases including alzheimer's
CN1305460C (zh) * 2001-04-13 2007-03-21 大塚制药株式会社 糖摄取的促进方法
ITBO20020140A1 (it) * 2002-03-21 2003-09-22 Valpharma Sa Formulazioni a base di nadh in forma di multiparticolato con rivestimento gastroresistente o a rilascio modificato
US20040126751A1 (en) * 2002-12-27 2004-07-01 Birkmayer Jorg G.D. Method of prolonging the life-span of living cells using NADH, NADPH and ADP-ribose
CA2678135C (en) * 2003-02-28 2012-12-04 Elc Management Llc Method for increasing hair growth using a creatine compound
US7666442B2 (en) * 2004-08-31 2010-02-23 Tracie Martyn International, Llc Topical compositions comprising benfotiamine and pyridoxamine
US7776915B2 (en) * 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
US20090246234A1 (en) * 2008-04-01 2009-10-01 Benjamin Johnson Therapeutic Treatment Using Niacin for Skin Disorders
US8642655B2 (en) 2011-03-09 2014-02-04 Benjamin Johnson Systems and methods for preventing cancer and treating skin lesions
US20220202844A1 (en) * 2020-12-31 2022-06-30 Richard Clark Kaufman Drug delivery composition and a method of administering the drug
US12150461B2 (en) 2021-05-04 2024-11-26 Sovida Solutions Ltd. Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
AU2022270419A1 (en) * 2021-05-04 2023-12-07 Sovida Solutions Ltd. Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof
CN116217895B (zh) * 2021-12-02 2025-08-19 中国科学院化学研究所 定向光催化合成的方法以及共轭聚合物的应用
DE202022000567U1 (de) 2022-03-06 2022-03-16 Penta Phi Eg Liposomale Formulierung
CN119157897A (zh) * 2023-10-12 2024-12-20 苏州人本药业有限公司 Nadph在制备治疗重性抑郁症、双向抑郁症、脑卒中后抑郁症或神经炎症药物的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256472A3 (en) * 1986-08-11 1988-09-07 Lion Corporation Cosmetic agent for application to skin
JPS63301810A (ja) * 1987-06-01 1988-12-08 Keikichi Sugiyama 毛髪用組成物
EP0331620B1 (de) * 1988-03-01 1993-08-11 Birkmayer, Walther, Prof. Dr. Mittel zur Behandlung des Parkinson-Syndroms
AT397201B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels
ATE156704T1 (de) * 1989-12-05 1997-08-15 Ramsey Foundation Neurologische wirkstoffe zur nasalen verabreichung an das gehirn
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
DE4100361C1 (enExample) * 1991-01-04 1992-04-23 Birkmayer, Joerg, Univ.-Prof. Ddr., Wien, At
DE4102240C1 (enExample) * 1991-01-24 1992-04-09 Birkmayer, Joerg, Univ.-Prof. Ddr., Wien, At
DE4218291A1 (de) * 1992-06-03 1993-12-09 Mattern Et Partner Pharmazeuti Dosierspray für pernasale Applikation
EP0615747B1 (en) * 1993-03-18 1999-09-29 Terumo Kabushiki Kaisha Hemoglobin-encapsulating liposome and method for making the same
US5332727A (en) * 1993-04-29 1994-07-26 Birkmayer U.S.A. Stable, ingestable and absorbable NADH and NADPH therapeutic compositions

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531490A (ja) * 1998-12-09 2002-09-24 カイロン コーポレイション 中枢神経系に薬剤を投与するための方法
JP2006512320A (ja) * 2002-11-19 2006-04-13 ヌートロピア エアネールングスメディツィニッシェ フォーシューンクス ゲゼルシャフト ミット ベシュレンクテル ハフトング Ｎａｄｈ／ｎａｄｐｈを含む組成物
JP2011144186A (ja) * 2002-11-19 2011-07-28 Nutropia Ernaehrungsmedizinische Forschungs Gmbh Ｎａｄｈ／ｎａｄｐｈを含む組成物

Also Published As

Publication number Publication date
US5952312A (en) 1999-09-14
CA2167104A1 (en) 1996-07-18
CA2735293A1 (en) 1996-07-18
US5654288A (en) 1997-08-05
US5750512A (en) 1998-05-12
JP2004002446A (ja) 2004-01-08
EP0722734A1 (en) 1996-07-24

Similar Documents

Publication Publication Date Title
US5750512A (en) NADH and NADPH therapeutic agents for nasal, sublingual, rectal and dermal administration
US8252325B2 (en) Liposome-encapsulated glutathione for oral administration
EP1115381B1 (en) Proteinic drug delivery system using membrane mimetics
US6608073B1 (en) Intranasal codeine for the rapid suppression of cough and rapid relief of pain
AU2006256518B2 (en) Method and composition for treating inflammatory disorders
TWI269652B (en) Transnasal anticonvulsive compositions and modulated process
JP2004509920A (ja) カテコールアミン医薬組成物および方法
JP2004509920A5 (enExample)
MXPA05001886A (es) Composiciones farmaceuticas para administracion bucal de medicamentos para liberacion de dolor.
IL182950A (en) Liposomal suspension for oral glutathione administration
US5668114A (en) NADH and NADPH pharmaceuticals for treating hypertension
US5712259A (en) NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
JPH06263644A (ja) リチウム治療剤
JPH01246221A (ja) フエノール含有鎮咳液体組成物
RS49889B (sr) Intraoralni ili intranazalni transmukozni preparat koji sadrži levosimendan
JP2001505222A (ja) 生物体にペプチド系医薬を導入するための局所用製剤
CN100479818C (zh) 治疗内耳疾病的药物配方和其应用方法
MX2012006352A (es) Tratamiento de alodinia e hiperalgesia.
WO1999007355A1 (en) Idebenone-containing preparation for percutaneous administration
WO2025185660A1 (zh) 一种高载药量分子态辛伐他汀皮肤用软膏剂及其制备和应用
AU2003263416B2 (en) Pharmaceutical compositions for buccal delivery of pain relief medications
CN119326740A (zh) 一种治疗生物节律失调的鼻脑递释制剂
WO2001035946A2 (en) Intranasal administration of raloxifene and tamoxifen
JPWO1999059580A1 (ja) 皮膚疾患予防治療剤
EA021712B1 (ru) Противовоспалительное средство для лечения контактного дерматита